Failure to efficiently, timely and effectively communicate clinical trial results and FDA actions can result in massive stock price declines, angry stockholders and employees, EMEA, FDA and SEC investigations, painful delays in future trials, and even compromised patient safety. Extreme care must be taken at each stage to manage your disclosures appropriately, keeping in mind legal, regulatory, market and public affairs concerns. Particular concern arises when shareholders expect details on FDA actions and a company is unable to give out any information without jeopardizing its relationship. This panel of experts discuss their experiences, and share suggestions for best practices, navigating the minefi eld of disclosure in the life sciences world.

• Educate target audience
• Relate useable information in an interactive manner
• Teach by conveying stories and concrete information on all consequences